Volume 3.00 | Jan 9

Pulmonary Cell News 3.00 January 9, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
Foxa3 Induces Goblet Cell Metaplasia and Inhibits Innate Antiviral Immunity
Researchers produced transgenic mice conditionally expressing Foxa3 in airway epithelial cells and developed human bronchial epithelial cells expressing Foxa3. FOXA3 was highly expressed in airway goblet cells from patients with asthma and COPD. [Am J Respir Crit Care Med] Abstract
View On-Demand Webinar: Optimized Differentiation of Bronchial Epithelial Cells
PUBLICATIONS (Ranked by impact factor of the journal)
Suppression of Interferon Lambda Signaling by SOCS-1 Results in Their Excessive Production during Influenza Virus Infection
Scientists observed that influenza virus induced robust expression of interferon lambda (IFN-?) in alveolar epithelial cells mainly through a RIG-I-dependent pathway, but IFN-?-induced phosphorylation of the signal transducer and activator of transcription protein 1 was dramatically inhibited in the infected cells. [PLoS Pathog] Full Article

Ex Vivo Chemical Cytometric Analysis of Protein Tyrosine Phosphatase Activity in Single Human Airway Epithelial Cells
Investigators describe a novel method for the measurement of protein tyrosine phosphatase activity in single human airway epithelial cells using capillary electrophoresis. [Anal Chem] Abstract

Inhibition of Airway Epithelial-to-Mesenchymal Transition and Fibrosis by Kaempferol in Endotoxin-Induced Epithelial Cells and Ovalbumin-Sensitized Mice
Researchers investigated whether 1-20?µM kaempferol inhibited lipopolysaccharide (LPS)-induced bronchial epithelial-to-mesenchymal transition (EMT) in BEAS-2B cells. LPS induced airway epithelial TGF-ß1 signaling that promoted EMT with concurrent loss of E-cadherin and induction of a-smooth muscle actin. [Lab Invest] Abstract

SWCNTs Induced Autophagic Cell Death in Human Bronchial Epithelial Cells
Scientists investigated the alterations in cellular response with morphological changes induced by single-walled carbon nanotubes (SWCNTs) in BEAS-2B cells, a human bronchial epithelial cell line. [Toxicol In Vitro] Abstract

S-Nitrosothiols Increases Cystic Fibrosis Transmembrane Regulator Expression and Maturation in the Cell Surface
Human bronchial airway epithelial cells expressing F508del cystic fibrosis transmembrane conductance regulator (CFTR) were exposed to S-nitrosoglutathione diethyl ester (GNODE) and S-nitroso-N-acetyl cysteine (SNOAC). The effects of these S-nitrosothiols on the expression and maturation of F508del CFTR were determined by cell surface biotinylation and Western blot analysis. Scientists also found for the first time that GNODE and SNOAC were effective at increasing CFTR maturation at the cell surface. [Biochem Biophys Res Commun] Abstract


A Reevaluation of CD22 Expression in Human Lung Cancer
Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer. The objective of the studies was to independently validate these results with the goal of testing the efficacy of CD22 immunotoxins on lung cancer cell lines. [Cancer Res] Abstract

Dickkopf-1 Is Oncogenic and Involved in Invasive Growth in Non Small Cell Lung Cancer
RT-PCR and Western blot were used to examine the expression of Dickkopf-1 (DKK1) in a panel of ten human non small cell lung cancer (NSCLC) cell lines and NSCLC tissues. DKK1 expression was highly transactivated in the great majority of these cancer lines. [PLoS One] Full Article

B-9-3, A Novel ß-Carboline Derivative Exhibits Anti-Cancer Activity via Induction of Apoptosis and Inhibition of Cell Migration In Vitro
In the present study, B-9-3 – a semi-synthetic compound that is formed of two harmane molecules bound by a butyl group – showed a strong anti-cancer activity against a human lung cancer cell line, a human breast cancer cell line, and a human colorectal carcinoma cell line. [Eur J Pharmacol] Abstract

Promoter Methylation-Mediated Downregulation of PRDM5 Contributes to the Development of Lung Squamous Cell Carcinoma
5-aza-2′-deoxycitydine inhibited the proliferation of SK-MES-1 cells and the growth of xenografts in nude mice, accompanied by reduced methylation of PRDM5 promoter and increased expression of PRDM5. [Tumor Biol] Abstract

MiR-27b Targets LIMK1 to Inhibit Growth and Invasion of NSCLC Cells
Researchers found that microRNA (miR)-27b was remarkably decreased in both non-small cell lung cancer (NSCLC) tissues and cell lines. Moreover, overexpression of miR-27b significantly suppressed NSCLC cells proliferation and invasion. [Mol Cell Biochem] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma
The authors provide an overview of the epidermal growth factor receptor (EGFR) pathway, review the significant somatic EGFR alterations in lung adenocarcinoma and highlight their implications for treatment. In addition, they examine pathways by which tumors resist EGFR tyrosine kinase therapy, both as primary nonresponders and by acquired resistance. [Lab Invest] Abstract

Second-Line Treatment in Advanced Non-Small-Cell Lung Cancer in the Epidermal Growth Factor Receptor Wild-Type Population: Review of Patient Profile
After progression during first-line treatment in advanced non-small-cell lung cancer, a large percentage of patients are candidates for second-line treatment. The majority do not have epidermal growth factor receptor-activating mutations. This article reviews the treatment options available for this subpopulation of patients, which includes essentially docetaxel, pemetrexed and erlotinib. [Anticancer Drugs] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Transgene Announces Topline Preliminary Results from Phase IIb Part of TIME Trial with TG4010 in Non-Small Cell Lung Cancer
Transgene SA announced topline preliminary results from the Phase IIb part of the Phase IIb/III TIME trial evaluating TG4010 MUC-1 targeted immunotherapy in combination with chemotherapy versus placebo plus chemotherapy in the first-line treatment of MUC-1 positive advanced non-small cell lung cancer patients. [Transgene SA] Press Release

Axelar Announces Final Data from Phase II Study with AXL1717 in Lung Cancer
Axelar AB announced the final results from its Phase II study AXL-003 in patients with non-small cell lung cancer. The final data showed no statistically significant difference in rate of progression-free survival between the patients treated with AXL1717 compared with the group treated with docetaxel, which confirms the previously communicated preliminary data. [Axelar AB] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals, Inc. announced that the company has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer. [Peregrine Pharmaceuticals, Inc.] Press Release

AIT Announces Phase II Study of NOxCureCF, a Respiratory Treatment for Cystic Fibrosis Patients Using a Nitric Oxide-Base Formulation
Advanced Inhalation Therapies announced that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis. [PR Newswire Association LLC] Press Release

Ludwig Cancer Research Bestows Half a Billion in New Funding to Six Eminent U.S. Research Institutions
Cancer research in the U.S. got a critical boost as the six Ludwig Centers at Johns Hopkins University, Harvard University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University and the University of Chicago received a total of $540 million as part of a gift from Ludwig Cancer Research, on behalf of its founder, Daniel K. Ludwig. [Ludwig Institute for Cancer Research Ltd] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Thoracic Society Of Australia And New Zealand Annual Meeting 2014 (TSANZ 2014)
April 4-9, 2014
Adelaide, Australia

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW PhD Position – Grading CIN in the Mammary Gland (European Molecular Biology Laboratory)

Postdoctoral Research Fellow – Lung Development, Injury/Repair and Fibrosis (Mayo Clinic)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Assistant Professor, Associate Professor, Professor – Lung Biology or Pulmonary and Critical Care Diseases (Boston University School of Medicine & Boston Medical Center)

Associate Scientist II/Scientist I – Respiratory, Autoimmunity and Inflammation Research (MedImmune)

PhD Position – Genetics of Non-Smoker Chronic Obstructive Pulmonary Disorders (Göttingen Center for Molecular Biosciences)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us